Study on Rotavirus Vaccine Administration at Birth
Overview of the Research
A recent study published in the New England Journal of Medicine assessed the effectiveness of administering the rotavirus vaccine starting at birth. This approach may prove to be more cost-effective and clinically beneficial, particularly in low-income countries. Rotavirus disease, which affects the gastrointestinal tract, primarily impacts infants early in life, leading to symptoms such as vomiting and diarrhea. In severe cases, it can necessitate hospitalization.
Current Vaccination Practices
In Ontario, the rotavirus vaccination schedule begins at eight weeks of age and has demonstrated substantial effectiveness in preventing rotavirus disease. However, in many low-income countries, access to the vaccine is limited. The high cost and reduced effectiveness of the vaccine in these regions raise concerns about the current vaccination strategy. An earlier administration, starting at birth, could potentially mitigate these issues.
Methodology of the Study
Researchers from the Murdoch Children’s Research Institute in Melbourne, Australia, conducted the study by recruiting eligible infants from health centers in Central Java and Yogyakarta, Indonesia. The participants were randomly assigned to receive either a neonatal vaccine schedule, an infant vaccine schedule, or a placebo. This double-blind study involved administering four doses of either the vaccine or the placebo. Conducting a placebo group in Indonesia was deemed ethical since rotavirus vaccination is not part of the Indonesian Immunization Program.
Primary Purpose and Follow-Up
The primary goal of the study was to analyze the efficacy of a neonatal vaccine schedule consisting of three doses: one at birth (between days zero and five), and two additional doses at eight weeks and fourteen weeks. The researchers followed up with the children until they reached 18 months of age.
Results on Protection Against Rotavirus Disease
The statistical analysis included over 1,500 infants. The findings revealed that severe rotavirus disease occurred in 5.6% of the placebo group, 1.4% in the neonatal-scheduling group, and 2.7% in the infant-scheduling group. At 18 months, the efficacy of the neonatal schedule was found to be 75%, compared to 51% for the infant schedule. These results confirm that administering the rotavirus vaccine at birth significantly protects against rotavirus disease.
Secondary Analysis and Immune Response
A secondary analysis focused on the immune response, measuring the shedding of the vaccine in stool samples post-administration. Blood samples were also collected to detect antibodies against rotavirus. The cumulative vaccine response was found to be 94% in the neonatal-scheduling group and 99% in the infant-scheduling group. The side effect profiles across the three treatment groups were identical.
Conclusion on the Efficacy of the Rotavirus Vaccine
The rotavirus vaccine is an effective preventive measure against rotavirus disease in children. In low-income countries like Indonesia, where high costs and low effectiveness hinder routine vaccination, an administration schedule beginning at birth may resolve these challenges. This study has established that an earlier neonatal rotavirus vaccination schedule is a viable strategy to combat rotavirus disease.
References
(1) Bines JE, Thobari JA, Satria CD, et al. Human neonatal rotavirus vaccine (RV3-BB) targets rotavirus from birth. The New England Journal of Medicine. 2018.
(2) Queens Printer For Ontario. Ontario’s Routine Immunization Schedule. Rotavirus. 2012. http://www.health.gov.on.ca/en/public/programs/immunization/static/immunization_tool.html#2-4mths